

# Respiratory Research Review™

Making Education Easy

Issue 91 - 2013

## In this issue:

- > *SMART in 'real-world' NZ*
- > *SMART-like in Europe*
- > *Asthma action plans*
- > *Maternal asthma controller use and perinatal outcomes*
- > *Impact of England's smoke-free legislation*
- > *Fast foods and allergy*
- > *NZ green-lipped mussel attenuates bronchoconstriction*
- > *Dupilumab in persistent asthma*
- > *Chronic propranolol dosing in asthma*
- > *Asthmatic granulomatosis: a novel disease*

### Abbreviations used in this issue

- FeNO** = fraction of exhaled nitric oxide  
**FEV<sub>1</sub>** = forced expiratory volume in 1 second  
**ICS** = inhaled corticosteroid  
**IL** = interleukin  
**LABA** = long-acting  $\beta_2$ -agonists  
**MDI** = metered dose inhaler  
**OR** = odds ratio

## Welcome to issue 91 of Respiratory Research Review.

Selecting articles authored by New Zealanders has been one of the guiding principles when selecting articles for this issue. NZ authors contribute widely to the international asthma literature.

Mitesh Patel and colleagues from the Medical Research Institute of NZ in Wellington investigate SMART (Single Inhaler Maintenance and Rescue Therapy) in a 'real-life' setting of 300 patients with a recent asthma exacerbation. Because they had *a priori* concerns of medication overuse, delayed seeking of medical review and ultimately a higher burden of corticosteroids, they used electronic monitors to measure date and time of MDI use. As outlined below, SMART therapy delivered in every aspect. The NZ study is followed by a European study using a SMART-type regimen using beclomethasone and formoterol, finding very similar positive outcomes. The SMART regimen was used inside a management plan, and an American group reminds us of the importance of such plans for therapy adherence and patient satisfaction.

Phillippa Ellwood from Auckland is using ISAAC data to describe a relationship between fast-food consumption and asthma, rhinitis and eczema, with milk, eggs, cereals, fruits and vegetables having protective effects. An American group reports an attenuating effect on bronchoconstriction after taking a lipid fraction extract of NZ green-lipped mussels. We finish off reviewing three articles: effect of an IL-4/IL-13 antagonist on asthma control, a trial of propranolol controlling asthma and the possible novel disease of asthmatic granulomatosis.

We hope you enjoy the selection, and we are happy to respond to feedback.

Kind regards

Associate Professor Lutz Beckett

[lutzbeckett@researchreview.co.nz](mailto:lutzbeckett@researchreview.co.nz)



2013  
 AUSTRALASIAN  
 TUBERCULOSIS  
 CONFERENCE 28-30 November | The Hilton, **Auckland** |  
[www.tbconference.co.nz](http://www.tbconference.co.nz)  
 LUNG HEALTH

Call for Abstracts and Registration Now OPEN

Treating  
 Asthma?  
 Think Seretide

Available in two  
 fully funded devices\*

\*Special Authority criteria apply.



Seretide  
 Fluticasone propionate/Salmeterol xinafoate



Before prescribing *Seretide*, please review the Data Sheet at [www.medsafe.govt.nz](http://www.medsafe.govt.nz). *Seretide* and *Accuhaler* are registered trade marks of the GlaxoSmithKline group of companies. Marketed by GlaxoSmithKline NZ. Limited, Auckland. **Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.**

TAPS DA1313IG/13JU/SFC/0016

For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

[www.researchreview.co.nz](http://www.researchreview.co.nz)

a RESEARCH REVIEW publication

## Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations

**Authors:** Patel M et al, for the SMART Study Group

**Summary:** Patients aged 16–65 years with a recent asthma exacerbation were randomised to SMART (two actuations of budesonide/formoterol 200µg/6µg twice daily via a combination MDI, with one additional actuation for symptom relief as needed; n=151) or a standard fixed-dose regimen (two actuations of budesonide/formoterol 200µg/6µg twice daily via a combination MDI with 1–2 actuations of salbutamol 100µg by MDI for symptom relief as needed; n=152). Compared with the standard regimen, SMART was associated with: i) no significant difference in the proportion of participants with  $\geq 1$  high-use episode of  $\beta$ -agonist (primary outcome; 84% vs. 68%; p=0.058); ii) significantly fewer days of high use (5.1 vs. 8.9; p=0.01); iii) significantly fewer days of high use without medical review among participants with  $\geq 1$  high-use episode (8.5 vs. 18.3; p=0.001); iv) significantly greater inhaled budesonide use (943.5 vs. 684.3 µg/day; p=0.006); v) significantly lower oral corticosteroid exposure (77.5 vs. 126.6mg prednisone; p=0.011); vi) no significant difference in composite systemic corticosteroid exposure (793.7 vs. 772.1mg prednisone equivalents per year; p=0.76); and vii) a significantly lower weighted mean severe asthma exacerbation rate (0.53 vs. 0.97; p=0.004).

**Comment:** The SMART regimen has been around for at least a decade – what is special about this article in the first edition of Lancet Respir Med? It is an investigator initiated trial funded by the Health Research Council of New Zealand. Patients were all-comers between the ages of 16 and 65 years with a physician diagnosis of asthma, and electronic monitors were used to monitor actual use. The results support the SMART regimen; SMART led to higher ICSs, but less oral steroid courses because of significantly fewer asthma exacerbations. **Bottom line: SMART has a favourable risk-benefit profile and can be recommended for adults with severe asthma.**

**Reference:** Lancet Respir Med 2013;1(1):32–42

<http://www.thelancet.com/journals/lanres/article/PIIS2213-2600%2813%2970007-9/fulltext>

## Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma

**Authors:** Papi A et al

**Summary:** Following a 2-week run-in period of beclometasone/formoterol 100µg/6µg per inhalation twice daily plus salbutamol 100µg as required via MDI, patients with asthma (not fully controlled, FEV<sub>1</sub>  $\geq 60\%$  of predicted) were randomly allocated to receive maintenance with beclometasone/formoterol 100µg/6µg twice daily with as-needed reliever therapy with either beclometasone/formoterol 100µg/6µg (evaluable n=852) or salbutamol 100µg (849). Compared with the salbutamol reliever group, the beclometasone/formoterol reliever group had a significantly longer time to first exacerbation (primary outcome: 209 vs. 134 days; hazard ratio 0.64 [95% CI 0.49, 0.82]; p=0.0005) and a significantly lower severe exacerbation rate (12% vs. 18%; p=0.0003). The beclometasone/formoterol reliever arm also had significantly better improvements for symptoms, days with mild exacerbations, asthma control days, reliever use and lung function parameters, and a similarly low rate of serious adverse events, compared with the salbutamol reliever arm.

**Comment:** This article, published in the same edition of the new Lancet Respir Med, examined a similar principle. This time the European investigators compared a low-dose extra-fine beclometasone/formoterol combination inhaler in two regimens: fixed-dose combination product and salbutamol as needed with the SMART instructions for the combination product. The main outcomes are: a) asthma can be controlled with a lower dose of extra-fine inhaler medications; b) overuse of  $\beta$ -agonist can be reduced; and c) **our bottom line: single inhaler maintenance and reliever treatment reduced the time to a severe asthma exacerbation.**

**Reference:** Lancet Respir Med 2013;1(1):23–31

<http://tinyurl.com/LancetResp-1-23>

EP/12/03 TAPS PP1690

Boehringer Ingelheim, Auckland

Please refer to the Data Sheet before prescribing

SPIRIVA®  
(tiotropium 18 mg)

For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

[www.researchreview.co.nz](http://www.researchreview.co.nz)

a RESEARCH REVIEW publication

## Asthma action plans and patient satisfaction among women with asthma

**Authors:** Patel MR et al

**Summary:** These authors performed a cross-sectional analysis of baseline data for 808 women with asthma who were participants in a randomised trial evaluating a self-management programme; 84% of the women were satisfied with their asthma care and 48% had a physician-written asthma action plan. Compared with women with an action plan, those without one were significantly less likely to: i) take their asthma medication as prescribed ( $p < 0.001$ ); ii) initiate a discussion about asthma with their physician ( $p < 0.001$ ); iii) own a peak flow meter ( $p < 0.001$ ); and iv) report being dissatisfied with their asthma care (adjusted OR 2.07 [95% CI 1.35, 3.17;  $p < 0.001$ ]).

**Comment:** Summarising large randomised trials for publication may create unintentional gaps in the message. Both of the above trials used their regimen in the framework of a written asthma management plan. These American authors went back to analyse data from two American trials, with the particular focus on the effect of an asthma management plan on women. They found that almost half of the participants did not have a management plan. **Bottom line: participants without a management plan were less likely to own a peak flow meter, take asthma medications and initiate discussion about asthma, and were less satisfied with their asthma management.**

**Reference:** *Chest* 2012;142(5):1143–9

<http://tinyurl.com/Chest-142-1143>

## Impact of maternal use of asthma-controller therapy on perinatal outcomes

**Authors:** Cossette B et al

**Summary:** These researchers analysed data for 7376 pregnancies in a cohort of Canadian women who had asthma while giving birth, 8.8% and 59.6% of which were associated with LABA and ICS exposure, respectively; all LABA recipients also received ICSs. The overall respective prevalences of low birthweight, preterm birth and small for gestational age were 7.7%, 9.5% and 13.5%. No association was seen between use of LABAs and these pregnancy outcomes, but nonsignificant trends were seen for increased prevalences with mean daily ICS fluticasone-equivalent doses of  $> 125 \mu\text{g}$ .

**Comment:** Uncontrolled asthma has been associated with low birthweight, preterm birth and small for gestational age. These Canadian authors reported, over a decade, on a cohort of woman with asthma giving birth. Of the 7376 pregnancies, 56.9% were exposed to an ICS and 8.8% to a LABA. Reassuringly, neither the use of a LABA nor the use of low/moderate dose of an ICS was associated with low birthweight, preterm birth or small for gestational age. It is less clear if the association with high-dose ICSs reflects a drug effect or more severe asthma. **Bottom line: standard asthma therapy including the use of LABAs appears to be safe in pregnancy.**

**Reference:** *Thorax* 2013;68(8):724–30

<http://thorax.bmj.com/content/68/8/724.abstract>

## Respiratory Research Review

**Independent commentary by Associate Professor Lutz Beckert,**  
Respiratory Physician at Christchurch Hospital.

For full bio [CLICK HERE](#)



Research Review publications are intended for New Zealand health professionals.

## SampleDrawer

– ORDER SAMPLES ANYTIME

SampleDrawer enables prescribers to order selected NZ pharmaceutical samples, including Alzheimer medications, exactly when they need them. Simply logon, order, and your samples arrive!

For more details go to [www.sampledrawer.co.nz](http://www.sampledrawer.co.nz)



Find out if your patients have their asthma under control by taking the **Asthma Control Test™**

[www.asthmacontrol.co.nz](http://www.asthmacontrol.co.nz)

TAPS DA1313IG/13JU/SFC/0016

For more information, please go to <http://www.medsafe.govt.nz>



### Short-term impact of the smokefree legislation in England on emergency hospital admissions for asthma among adults

**Authors:** Sims M et al

**Summary:** This population-based research, using a generalised additive model adjusted for seasonality, variation in population size and region-specific, nonlinear, long-term trends, found that England's smoke-free legislation resulted in an immediate 4.9% reduction in adult emergency admissions for asthma, or an estimated reduction of 1900 admissions annually during the first 3 years since the legislation was introduced.

**Comment:** This article uses rather complex statistics to ensure robust data modelling. The researchers explored the impact of the 'natural' experiment of the July 1<sup>st</sup>, 2007 introduction of smoke-free legislation on the number of adult emergency admissions. Similar studies have been published for Ireland, Kentucky, Delaware and NZ, reporting reductions of 5–40% (NZ 16%); however, many of these studies had methodological limitations. The year following the introduction of the smoke-free legislation, about 1900 admissions with asthma were prevented in the UK.

**Bottom line:** smoke-free legislation reduced asthma admissions by about 5% a year.

**Reference:** *Thorax* 2013;68(7):619–24

<http://thorax.bmj.com/content/68/7/619.abstract>

### SUBSCRIBING TO RESEARCH REVIEW

To subscribe or download previous editions of Research Review publications go to

[www.researchreview.co.nz](http://www.researchreview.co.nz)

**Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time.

**Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.



## SINGULAIR® (montelukast sodium)

– the pill that can enhance your patients' asthma control.<sup>1,2</sup>

Now there's an easy way to complement your patients' existing asthma treatments - SINGULAIR.<sup>1,2</sup> It's an easy to take once-a-day pill.<sup>2</sup> And it's easy to obtain because it's fully funded under GP Special Authority.<sup>3</sup> Plus, in patients (≥18 years old) insufficiently controlled with ICS or ICS+LABA, the addition of daily SINGULAIR significantly improved both asthma control and asthma related quality of life (p<0.001 vs baseline).<sup>1</sup> So, consider enhancing asthma control with the pill used by over 110 million patients around the world, now funded in New Zealand.<sup>3,4</sup>

SINGULAIR – the easy add-on for asthma.<sup>2-4</sup>



ONCE DAILY  
**SINGULAIR**®  
(montelukast sodium)

Tablet shown not actual size. Adapted from Virchow et al with permission from Informa Healthcare.<sup>1</sup> ICS=inhaled corticosteroid; LABA=long-acting β-agonist; A 6-month, prospective, open-label, observational study, with a 6-month extension, of 1,681 patients ≥18 years with mild to moderate asthma insufficiently controlled by ICS or ICS + LABA treatment. At Visit 1 (baseline), asthma control was assessed with the 5-question Asthma Control Test (ACT), the primary end point, and asthma-related quality of life was assessed using the mini-Asthma Quality-of-Life Questionnaire (mini-AQLQ) (Juniper). Spirometry was measured if considered necessary by the physician. Patients received SINGULAIR 10 mg for self-administration at Visit 1 in addition to their current asthma treatment (SABA, ICS, LABA, fixed combinations of ICS + LABA, theophylline, or oral corticosteroids). Additional visits were scheduled after 3, 6, 9, and 12 months. Efficacy analyses were performed for the intention-to-treat and per-protocol populations, whereas safety was evaluated using the total set of patients. **References:** 1. Virchow JC et al. *Resp Med*. 2010;104(6):644-651. 2. SINGULAIR (montelukast sodium) Datasheet 24 October 2011, MSD New Zealand Limited. 3. PHARMAC Special Authority Form SA1227. 4. Data on file, MSD. A 3rd party analysis of IMS data including ages 6 months and older: IMS Midas Sales, IMS National Disease and Therapeutic Index (NDTI) and Thomson Reuters MedStat, IMS data accessed June 2011. All rights reserved.

**SINGULAIR (montelukast) 4mg chewable tablets, 5mg chewable tablets, 10mg tablets. Prescription Only Medicine. Use:** SINGULAIR is for use in adults and children (2-15 yrs) for the prevention and chronic treatment of asthma, including the prevention of day- and night-time symptoms and the prevention of exercise-induced bronchospasm (narrowing of airways), and for the relief of daytime and night-time symptoms of seasonal and perennial allergic rhinitis. **When not to use:** SINGULAIR should not be taken in patients who have a hypersensitivity reaction to any of the ingredients. **Precautions:** SINGULAIR should not be used to treat acute asthma attacks. Inhaled or oral corticosteroids if appropriate should be reduced gradually. Common side effects: abdominal pain, headache and thirst. SINGULAIR is fully funded – under special authority for those who meet specified criteria. SINGULAIR may be taken with or without food. Interactions: N/A. All medicines have risks and benefits. Talk to your doctor to see if SINGULAIR is right for you. A doctor's visit fee and prescription charge will apply. Use only as directed and if symptoms continue or you have side effects, see your doctor, pharmacist, or health professional. Based on datasheet prepared 20 April 2010. **Supplied by:** Merck Sharp & Dohme (NZ) Limited, Newmarket, Auckland. For additional product information, consult the data sheet and/or Consumer Medicine Information (CMI), available on request (phone 0800 500 673) or at the Medsafe website [www.medsafe.govt.nz](http://www.medsafe.govt.nz). RESP-1077701-0000 03/13. TAPS DA 1613MM. BCG2-H SIN0029.



For more information, please go to <http://www.medsafe.govt.nz>

## Do fast foods cause asthma, rhinoconjunctivitis and eczema?

**Authors:** Ellwood P et al, the ISAAC Phase III Study Group

**Summary:** This paper reported global findings from phase III of the ISAAC (International Study of Asthma and Allergies in Childhood), in which patients aged 13–14 years and parents/guardians of children aged 6–7 years completed questionnaires on asthma, rhinoconjunctivitis, eczema and food intake behaviours over a 12-month period. Consumption of fruit  $\geq 3$  times per week was associated with an apparent protective effect against severe asthma in adolescents and children (respective ORs 0.89 [95% CI 0.82, 0.97] and 0.86 [0.76, 0.97]), while consumption of fast food  $\geq 3$  times per week increased the severe asthma risk (1.39 [1.30, 1.49] and 1.27 [1.13, 1.42]) and risks of severe rhinoconjunctivitis and severe eczema.

**Comment:** In this study, the Auckland-led research group interrogated the ISAAC database to correlate self-reported asthma symptoms with different dietary behaviours from 319,196 adolescents and 181,631 children. The main results were that milk, eggs, meat, fruit, cereal and vegetables were either protective or associated with less severe wheeze or rhinitis if consumed  $\geq 3$  times per week. Particularly in adolescents, the consumption of fast food, butter, margarine and pasta were all positively associated with asthma. **Bottom line: fast food may contribute to increased asthma, rhinoconjunctivitis and eczema in adolescents and children.**

**Reference:** *Thorax* 2013;68(4):351–60

<http://thorax.bmj.com/content/68/4/351>

**CLICK HERE**

to read previous issues of

**Respiratory Research Review**

## Marine lipid fraction PCSO-524™ (lyprinol®/omega XL®) of the New Zealand green lipped mussel attenuates hyperpnea-induced bronchoconstriction in asthma

**Authors:** Mickleborough TD et al

**Summary:** Patients with asthma and documented hyperventilation-induced bronchoconstriction received 3 weeks of dietary supplementation with NZ Green-lipped mussel extract (PCSO-524™) and placebo in a randomised, crossover design with a 2-week washout. Compared with placebo and pretreatment usual diet, the inclusion of PCSO-524™ was associated with a significant reduction in maximum fall in post-eucapnic voluntary hyperpnoea FEV<sub>1</sub> (–8.4% vs. –22.5% and –19.3%, respectively;  $p < 0.05$ ). PCSO-524™ also significantly reduced rescue medication use and pre- and post-eucapnic voluntary hyperpnoea levels of exhaled breath condensate cysteinyl leukotrienes and 8-isoprostane and urinary 9 $\alpha$ , 11 $\beta$ -prostaglandin-F<sub>2</sub> and Clara (CC16) protein, while exhaled breath condensate pH and asthma symptom scores were significantly improved ( $p < 0.05$  for all).

**Comment:** These American authors investigated the effect of a NZ green-lipped mussel extract. They recruited 20 participants with asthma and randomised them in a crossover design to receive either the mussel extract or placebo. Their endpoints were a loss of asthma control using eucapnic hyperventilation, FeNO and breath condensate markers. Participant using the mussel extract had a lesser fall in FEV<sub>1</sub> after challenge testing, lower levels of FeNO and a reduction of inflammatory markers in exhaled breath condensate. **Bottom line: the mussel extract seems to reduce airway inflammation and provide protection against hyperventilation-induced bronchoconstriction.**

**Reference:** *Respir Med* 2013;107(8):1152–63

<http://www.resmedjournal.com/article/S0954-6111%2813%2900139-X/abstract>

# Symbicort® SMART\* Complete asthma therapy. In ONE inhaler.

Only Symbicort SMART delivers rapid relief from symptoms AND effective asthma prevention in one inhaler.<sup>1</sup>



**Reference:** 1. Symbicort Turbuhaler Data Sheet 4 March 2013. Patients must meet eligibility criteria to be prescribed combination asthma treatment with Symbicort SMART. Before prescribing please refer to the full product data sheet available at [www.medsafe.govt.nz](http://www.medsafe.govt.nz). Symbicort is a fully funded Prescription Medicine. Special authority criteria and a prescription charge will apply, please refer to the Pharmaceutical Schedule. Symbicort® Turbuhaler® 100/6 (budesonide 100 mcg and eformoterol fumarate 6 mcg per metered dose) or Symbicort® Turbuhaler® 200/6 (budesonide 200 mcg and eformoterol fumarate 6 mcg per metered dose) or Symbicort® Turbuhaler® 400/12 (budesonide 400 mcg and eformoterol fumarate 12 mcg per metered dose). Symbicort 400/12 is not approved for use in the Symbicort SMART regime. **Approved indication:** For the regular treatment of asthma where use of combination inhaled corticosteroid and long acting beta-agonist is appropriate using either Symbicort Maintenance and Reliever Therapy (SMART) or Symbicort maintenance therapy. **Contraindications & Precautions:** Hypersensitivity to budesonide, eformoterol or inhaled lactose. Symbicort should not be initiated as emergency treatment for severe exacerbations or for patients with acutely worsening asthma symptoms. Care required for HPA axis suppression, when co-administering with inhibitors of CYP3A4 (e.g. ketoconazole, beta-blockers) or in patients with tuberculosis, severe cardiovascular disorders, diabetes, untreated hypokalaemia or thyrotoxicosis, pregnancy and lactation. **Common side effects** include headache, palpitations, tremor, oral candidiasis, mild throat irritation, coughing and hoarseness. Symbicort® and Turbuhaler® are trademarks of the AstraZeneca Group. AstraZeneca Limited, P299 Private Bag 92175, Auckland 1142. Telephone (09) 306 5650 or Facsimile (09) 306 5651. DA1013GF AUGUST 2013 essence AZ6302V4.

**AstraZeneca**  
Health Connects Us All

\*Symbicort Maintenance And Reliever Therapy

For more information, please go to <http://www.medsafe.govt.nz>

[www.researchreview.co.nz](http://www.researchreview.co.nz)

a RESEARCH REVIEW publication

## Dupilumab in persistent asthma with elevated eosinophil levels

**Authors:** Wenzel S et al

**Summary:** Patients with persistent, moderate-to-severe asthma (blood eosinophil count  $\geq 300$  cells/ $\mu$ L or a sputum eosinophil level  $\geq 3\%$ ) who used medium- to high-dose ICSs (tapered and discontinued over weeks 6–9) and LABAs (continued until week 4) received subcutaneous dupilumab 300mg (n=52) or placebo (n=52) once weekly. Compared with placebo, dupilumab was associated with a significantly lower asthma exacerbation rate (6% vs. 44%; OR 0.08 [95% CI 0.02, 0.28;  $p < 0.001$ ]), significant improvements in most lung function and asthma control measures, and reductions in biomarkers associated with Th2-driven inflammation, but more injection-site reactions, nasopharyngitis, nausea and headache.

**Comment:** It is exciting to see that after decades of fine tuning inhaler therapy, new asthma therapies are emerging targeting cytokinetic regulators of eosinophils, like this antibody against the  $\alpha$  subunit of the IL-4 receptor. Michael Wechsler's editorial ([N Engl J Med 2013;368\[26\]:2511–3](http://www.nejm.org/doi/full/10.1056/NEJMoa1304048)) makes compelling reading. He gives an overview of emerging asthma therapies, and clarifies that in this phase IIa safety study, only 21% of screened subjects were enrolled and dupilumab only showed an effect after standard therapy with ICSs and LABAs had been withdrawn. **Bottom line: the role of biological agents in the 'real world' is as yet undefined.**

**Reference:** *N Engl J Med* 2013;368(26):2455–66

<http://www.nejm.org/doi/full/10.1056/NEJMoa1304048>

## Randomized placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma

**Authors:** Short PM et al

**Summary:** Patients with mild-to-moderate, ICS-treated asthma received propranolol titrated as tolerated over 6–8 weeks to a maximum dosage of 80 mg/day and placebo in a crossover design; all participants received tiotropium for the first 4–6 weeks of each treatment period. There were no significant between-group differences for post-treatment methacholine and histamine challenges. A partial attenuation of albuterol recovery at 20 minutes after histamine challenge was seen with propranolol versus placebo (FEV<sub>1</sub>% mean difference 5.28 [95% CI 2.54, 8.01];  $p = 0.001$ ). A small deterioration of 2.4% was seen in predicted FEV<sub>1</sub> after chronic  $\beta$ -blockade ( $p = 0.055$ ). There were no significant differences for mini-asthma quality of life questionnaire and asthma control questionnaire scores.

**Comment:** We have previously commented in Respiratory Research Review ([Issue 49](#)) on the potential use of  $\beta$ -blockers in asthma to reduce airway responsiveness to methacholine. This matches nicely with animal data, where 'knockout mice' without a  $\beta_2$ -receptor demonstrate less airway hyper-responsiveness, less mucus hyperplasia and less eosinophilia. It is somewhat disappointing that this trial of propranolol in patients with well-controlled mild to moderately severe asthma tolerated propranolol, but showed a loss in FEV<sub>1</sub> and no effect of protecting from methacholine or histamine challenge. **Bottom line:  $\beta$ -blockers remain contraindicated in asthma.**

**Reference:** *Am J Respir Crit Care Med* 2013;187(12):1308–14

<http://www.atsjournals.org/doi/abs/10.1164/rccm.201212-2206OC>

## Asthmatic granulomatosis: a novel disease with asthmatic and granulomatous features

**Authors:** Wenzel SE et al

**Summary:** These authors reported pathobiological findings from 10/19 patients with difficult-to-treat severe asthma requiring daily systemic corticosteroid use. As well as small airway changes consistent with asthma, interstitial non-necrotising granulomas were seen on pathology in these ten patients. There was no evidence of hypersensitivity pneumonitis, but 70% had a personal or family history of autoimmune-like disease. The ten case patients received treatment with azathioprine, mycophenolic acid, methotrexate or infliximab, which resulted in a decrease in corticosteroid requirements with improved or maintained FEV<sub>1</sub> in nine of them. Six of the other nine patients manifested asthmatic small airway disease alone or with alveolar septal mononuclear cells, but no granulomas, while three had other pathological findings such as aspiration, pneumonia or thromboemboli.

**Comment:** It does not happen often nowadays that a new disease is being described. Like many of us, these authors struggle with a small group of about 5–10% of patients with typical asthma who are difficult to manage. They identified a group of 19 out of 170 patients from a severe asthma clinic, and performed video-assisted thoracoscopic lung biopsies, taking a generous wedge resection including deep tissue. The authors reported a group with typical asthma pathology and also ill-defined, non-necrotising granulomas. They reported some success treating this group with azathioprine. **Bottom line: asthma granulomatosis may be a different disease explaining difficult-to-control asthma.**

**Reference:** *Am J Respir Crit Care Med* 2012;186(6):501–7

<http://tinyurl.com/AJRCCM-186-501>

# DUOLIN is fully funded.

Duolin HFA treats COPD, bronchitis and emphysema.

Duolin is an HFA inhaler meaning it is CFC free.

See Duolin data sheet at [www.medsafe.govt.nz](http://www.medsafe.govt.nz) before prescribing. Marketed by REX Medical Ltd, Auckland. TAPS: NA 5649

For more information, please go to <http://www.medsafe.govt.nz>

[www.researchreview.co.nz](http://www.researchreview.co.nz)

a RESEARCH REVIEW publication

